Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide

Fig. 1

Responses of castration-resistant prostate cancer patients after second-line flutamide therapy. a, b Waterfall plots in patients treated with abiraterone (a) and enzalutamide (b). c, d Percent change in PSA in patients treated with abiraterone (c) and enzalutamide (d). e, f PSA-progression-free survival curves in patients treated with abiraterone (e) and enzalutamide (f). AATF, antiandrogen alternative therapy with flutamide

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us